Wells Fargo & Company Issues Positive Forecast for Omnicell (NASDAQ:OMCL) Stock Price

Omnicell (NASDAQ:OMCL) had its price objective upped by Wells Fargo & Company from $52.00 to $55.00 in a report issued on Thursday morning,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock.

OMCL has been the subject of a number of other reports. KeyCorp upgraded Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price target for the company in a research note on Wednesday, January 7th. Weiss Ratings downgraded Omnicell from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, March 2nd. Bank of America upgraded Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price target for the company in a research note on Wednesday, February 4th. Piper Sandler reiterated an “overweight” rating and issued a $49.00 price target (down from $63.00) on shares of Omnicell in a research note on Friday, February 6th. Finally, UBS Group set a $60.00 target price on Omnicell and gave the company a “buy” rating in a research note on Friday, March 13th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $59.00.

Omnicell Stock Down 0.8%

NASDAQ:OMCL opened at $36.37 on Thursday. The company has a market capitalization of $1.65 billion, a price-to-earnings ratio of 909.48, a price-to-earnings-growth ratio of 1.31 and a beta of 0.85. Omnicell has a one year low of $22.66 and a one year high of $55.00. The stock has a 50-day simple moving average of $36.82 and a 200 day simple moving average of $39.08. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.22 and a current ratio of 1.43.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, February 5th. The company reported $0.40 EPS for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). The firm had revenue of $313.98 million during the quarter, compared to analyst estimates of $313.36 million. Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter last year, the business posted $0.60 earnings per share. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. Sell-side analysts predict that Omnicell will post 0.92 EPS for the current fiscal year.

Insider Buying and Selling at Omnicell

In other news, EVP Corey J. Manley sold 7,405 shares of Omnicell stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $34.69, for a total transaction of $256,879.45. Following the sale, the executive vice president owned 96,717 shares of the company’s stock, valued at approximately $3,355,112.73. The trade was a 7.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 2.52% of the company’s stock.

Institutional Investors Weigh In On Omnicell

A number of hedge funds have recently made changes to their positions in OMCL. AQR Capital Management LLC raised its holdings in shares of Omnicell by 42.1% during the first quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock valued at $627,000 after buying an additional 5,311 shares during the last quarter. Empowered Funds LLC raised its holdings in shares of Omnicell by 14.3% during the first quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock valued at $348,000 after buying an additional 1,243 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Omnicell by 4.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company’s stock valued at $4,337,000 after buying an additional 4,866 shares during the last quarter. Jane Street Group LLC raised its holdings in shares of Omnicell by 201.5% during the first quarter. Jane Street Group LLC now owns 163,664 shares of the company’s stock valued at $5,722,000 after buying an additional 109,382 shares during the last quarter. Finally, Creative Planning raised its holdings in shares of Omnicell by 16.7% during the second quarter. Creative Planning now owns 9,390 shares of the company’s stock valued at $276,000 after buying an additional 1,347 shares during the last quarter. Institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.